The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1
The ability to distinguish hepatocellular carcinoma (HCC) from metastatic carcinoma (MC) involving the liver and cholangiocarcinoma (CC) by immunohistochemistry has been limited by the lack of a reliable positive marker for hepatocellular differentiation. Arginase-1 is a marker for HCC recently described in some literature.
To examine the immunohistochemical staining of arginase-1 in cases of HCC, MC involving the liver and CC as compared to hepatocyte paraffin antigen -1 (HepPar-1) in an attempt to further define the diagnostic utility of arginase-1 in differentiating these tumors.
Materials and methods
A comparative immunohistochemical study of arginase-1 and HepPar-1expression was performed in 50 HCC cases, 38 cases of MC to the liver from varying sites, 12 cases of CC and 10 specimens of normal liver tissues. The predictive capacity of arginase-1 and HepPar-1 staining was determined using sensitivity, specificity, positive predictive value, and negative predictive value calculations.
All normal liver tissues (no=10), non- neoplastic cirrhotic liver tissues adjacent to HCC (no=42) as well as those adjacent to MC (no= 9) showed diffuse and strong immunostaining for both arginase-1 and HepPar-1. Arginase-1 demonstrated positive immunoreactivity in 42 of 50 (84%) cases of HCC compared with 35 of 50 (70%) for HepPar-1. Only one of 38 (2.6%) cases of MC and one of 12 (8.3%) cases of CC showed positive immunoreactivity for arginase-1. In contrast, HepPar-1 immunoreactivity was detected in 6 of 38 (15.8%) cases of MC and in 2 of 12 (16.7%) cases of CC. Arginase -1 showed a significantly higher sensitivity for HCC diagnosis (84%) compared to HepPar -1(70%) (p=0.016). The specificity of arginase-1 for HCC diagnosis was higher (96%) than that of HepPar -1 (84%); nevertheless, this was not statistically significant (p=0.109). Howerver, the combination of both immunomarkers for the diagnosis of HCC, raised the specificity to 100%.
Arginase-1 immunostaining has a higher sensitivity and specificity than HepPar-1 for HCC diagnosis. Furthermore, the combined use of arginase-1 and HepPar-1 can provide a potentially promising tool to improve the accuracy in distinguishing HCC from metastatic carcinoma and cholangiocarcinoma.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9991436558072434.
- Waly Raphael S, Yangde Z, Yuxiang C: Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012, 2012:421673.
- Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA: Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 2008,659(1–2):176–184.
- Aleem E, Elshayeb A, Elhabachi N, Mansour AR, Gowily A, Hela A: Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. Oncol Lett 2012,3(3):704–712.
- Lamps LW, Folpe AL: The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Adv Anat Pathol 2003,10(1):39–43. CrossRef
- Fujiwara M, Kwok S, Yano H, Pai RK: Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol 2012,120(4):230–237. CrossRef
- Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 2010,34(8):1147–1154. CrossRef
- Kakar S, Gown AM, Goodman ZD, Ferrell LD: Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007, 131:1648–1654.
- Lau SK, Prakash S, Geller SA, Alsabeh R: Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma,and metastatic adenocarcinoma. Hum Patho 2002, 33:1175–1181. CrossRef
- Chu PG, Ishizawa S, Wu E, Weiss LM: Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002, 26:978–988. CrossRef
- Kakar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ: Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 2003, 119:361–366. CrossRef
- Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA: Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997, 10:686–692.
- Wang L, Vuolo M, Suhrland MJ, Schlesinger K: HepPar1, MOC-, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006, 50:257–262. CrossRef
- Fan Z, van de Rijn M, Montgomery K, Rouse RV: Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003, 16:137–144. CrossRef
- Leong AS, Sormunen RT, Tsui WM, Liew CT: Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology 1998, 33:318–324. CrossRef
- Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, Jothy S: Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol 2008, 21:817–825. CrossRef
- Zynger DL, Everton MJ, Dimov ND, Chou PM, Yang XJ: Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008, 130:224–230. CrossRef
- Hishinuma M, Ohashi KI, Yamauchi N, Kashima T, Uozaki H, Ota S, Kodama T, Aburatani H, Fukayama M: Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein- producing gastric carcinoma. Histopathology 2006, 49:479–486. CrossRef
- Choi S, Park C, Ahn M, Lee JH, Shin T: Immunohistochemical study of arginase 1 and 2 in various tissues of rats. Acta Histochem 2012,114(5):487–494. CrossRef
- Multhaupt H, Fritz P, Schumacher K: Immunohistochemical localisation of arginase in human liver using monoclonal antibodies against human liver arginase. Histochemistry 1987, 87:465–470. CrossRef
- Sekine S, Ogawa R, Mcmanus MT, Kanai Y, Hebrok M: Dicer is required for proper liver zonation. J Pathol 2009, 219:365–372. CrossRef
- Theise ND, Curado MP, Franceschi S: Hepatocellular carcinoma. In WHO Classification of Tumors of the Digestive System. 4th edition. Edited by: Bosman FT, Carneiro F, Hruban RH, Theise ND. IARC Press, Lyon, France; 2010:205–216.
- Shiran MS, Isa MR, Sherina MS, Rampal L, Hairuszah I, Sabariah AR: The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Malays J Pathol 2006,28(2):87–92.
- Hajósi-Kalcakosz S, Dezső K, Bugyik E, Bödör C, Paku S, Pávai Z, Halász J, Schlachter K, Schaff Z, Nagy P: Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol 2012, 7:86. CrossRef
- Hong H, Patonay B, Finley J: Unusual reticulin staining pattern in well-differentiated hepatocellular carcinoma. Diagn Pathol 2011, 6:15. CrossRef
- Timek DT, Shi J, Liu H, Lin F: Arginase-1, HepPar-1, and Glypican-3 Are the Most Effective Panel of Markers in Distinguishing Hepatocellular Carcinoma From Metastatic Tumor on Fine-Needle Aspiration Specimens. Am J Clin Pathol 2012,138(2):203–210. CrossRef
- McKnight R, Nassar A, Cohen C, Siddiqui MT: Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol 2012,120(4):223–229. CrossRef
- Taylor SL, Haque S: Hepatobiliary pathology. Curr Opin Gastroenterol 2011,27(3):248–255. CrossRef
- Guo X, Xiong L, Zou L, Sun T, Zhang J, Li H, Peng R, Zhao J: L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival. Diagn Pathol 2012, 7:96. CrossRef
- Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J: Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagn Pathol 2012, 7:44. CrossRef
- Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z: Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol 2011, 6:121. CrossRef
- Chu PG, Weiss LM: Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol 2004,121(6):884–892. CrossRef
- Wennerberg AE, Nalesnik MA, Coleman WB: Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993,143(4):1050–1054.
- Iida H, Hata M, Kakuno A, Hirano H, Yamanegi K, Yamada N, Ohyama H, Terada N, Yasui C, Yamanaka N, Nakasho K: Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas. Oncol Lett 2011,2(6):1041–1046.
- Cao W, Sun B, Feitelson MA, Wu T, Tur-Kaspa R, Fan Q: Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer 2009,124(12):2886–2892. CrossRef
- The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- October 2012
- Online ISSN
- BioMed Central
- Additional Links
- Hepatocellular carcinoma
- Metastatic carcinoma